Pyxis Oncology Analyst Ratings
Pyxis Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 201.72% | RBC Capital | → $7 | Initiates Coverage On | → Outperform |
| 07/31/2023 | 546.55% | EF Hutton | → $15 | Initiates Coverage On | → Buy |
| 03/23/2023 | 503.45% | Credit Suisse | → $14 | Reiterates | → Outperform |
| 11/02/2021 | 589.66% | B of A Securities | → $16 | Initiates Coverage On | → Neutral |
| 11/02/2021 | 977.59% | Jefferies | → $25 | Initiates Coverage On | → Buy |
| 11/02/2021 | 718.97% | Credit Suisse | → $19 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/05/2023 | 201.72% | 加拿大皇家银行资本 | →$7 | 开始承保 | →跑赢大盘 |
| 07/31/2023 | 546.55% | EF Hutton | →$15 | 开始承保 | →购买 |
| 03/23/2023 | 503.45% | 瑞士信贷 | →$14 | 重申 | →跑赢大盘 |
| 11/02/2021 | 589.66% | B of A证券 | →$16 | 开始承保 | →中性 |
| 11/02/2021 | 977.59% | 杰富瑞 | →$25 | 开始承保 | →购买 |
| 11/02/2021 | 718.97% | 瑞士信贷 | →$19 | 开始承保 | →跑赢大盘 |
What is the target price for Pyxis Oncology (PYXS)?
Pyxis Oncology(PYXS)的目标价格是多少？
The latest price target for Pyxis Oncology (NASDAQ: PYXS) was reported by RBC Capital on September 5, 2023. The analyst firm set a price target for $7.00 expecting PYXS to rise to within 12 months (a possible 201.72% upside). 3 analyst firms have reported ratings in the last year.
加拿大皇家银行资本于2023年9月5日报道了Pyxis Oncology(纳斯达克：PYXS)的最新目标价。这家分析公司将目标价定为7美元，预计PYXS将在12个月内上涨至(可能上涨201.72%)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Pyxis Oncology (PYXS)?
Pyxis Oncology(PYXS)最近的分析师评级是多少？
The latest analyst rating for Pyxis Oncology (NASDAQ: PYXS) was provided by RBC Capital, and Pyxis Oncology initiated their outperform rating.
纳斯达克(Sequoia Capital：PYXS)对PYXIS肿瘤学的最新分析师评级是由加拿大皇家银行资本提供的，PYXIS肿瘤学发起了其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Pyxis Oncology (PYXS)?
Pyxis Oncology(PYXS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pyxis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pyxis Oncology was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Pyxis Oncology的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Pyxis肿瘤学的上一次评级是在2023年9月5日提交的，所以你应该预计下一次评级将在2024年9月5日左右的某个时候提供。
Is the Analyst Rating Pyxis Oncology (PYXS) correct?
分析师对Pyxis Oncology(PYXS)的评级正确吗？
While ratings are subjective and will change, the latest Pyxis Oncology (PYXS) rating was a initiated with a price target of $0.00 to $7.00. The current price Pyxis Oncology (PYXS) is trading at is $2.32, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Pyxis Oncology(PYXS)评级是以0.00美元至7.00美元的目标价启动的。目前Pyxis Oncology(PYXS)的交易价格为2.32美元，在分析师的预测范围内。